TrialAnnals of the rheumatic diseases2016

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.

Christina Charles-Schoeman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.